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One in seven couples worldwide are infertile, and male factor infertility accounts for approximately 30%–50% of these cases. Although
many genes are known to be essential for gametogenesis, there are surprisingly few monogenic mutations that have been conclusively
demonstrated to cause human spermatogenic failure. A nuclear receptor, NR5A1 (also called steroidogenic factor 1), is a key transcrip-
tional regulator of genes involved in the hypothalamic-pituitary-steroidogenic axis, and it is expressed in the steroidogenic tissue of the
developing and adult human gonad. Mutations of NR5A1 have been reported in 46,XY disorders of sex development and in 46,XX
primary ovarian insufficiency. To test the hypothesis that mutations in NR5A1 cause male infertility, we sequenced NR5A1 in
315 men with idiopathic spermatogenic failure. We identified seven men with severe spermatogenic failure who carried missense muta-
tions in NR5A1. Functional studies indicated that these mutations impaired NR5A1 transactivational activity. We did not observe these
mutations in more than 4000 control alleles, including the entire coding sequence of 359 normospermic men and 370 fertile male
controls. NR5A1 mutations are found in approximately 4% of men with otherwise unexplained severe spermatogenic failure.Introduction
It is estimated that one in seven couples worldwide have
problems conceiving.1 In recent years there has been
increasing concern about a possible decline in reproduc-
tive health, and this trend is paralleled by an increasing
demand for infertility treatments. As many as 8% of chil-
dren in someWestern countries are born as a result of assis-
ted reproductive techniques.2 Sperm counts in several
European countries are declining, and in Denmark 20%
of healthy young adult males have sperm concentrations
below the World Health Organization reference level of
20 3 106 sperm/ml.1,3 In the majority of cases, the under-
lying cause of male infertility is unknown. Familial clus-
tering of male subfertility as well as families with multiple
infertile or subfertile men, in whom an autosomal-reces-
sive or -dominant mutation with sex-limited expression
is likely to be present, indicates a genetic contribution to
spermatogenic failure.4–6 A chromosomal anomaly is
carried by 5% of all infertile men (such as 47,XXY Klinefel-
ter syndrome), and microdeletions of the long arm of the
Y chromosome (MIM 415000) are present in 10% of azoo-
spermic or severely oligozoospermic (< 1 3 106 sperm/ml)
men.7 Although rodent studies indicate that multiple
genes have the potential to cause male infertility, only
a few single-gene defects that cause male infertility have
been identified in humans. These include AURKC (MIM
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The Americgellar polyploid spermatozoa (MIM 243060), SPATA16
(MIM 609856) mutations associated with globozoosper-
mia (MIM 102530), CATSPER1 (MIM 606389) mutations
associated with recessive male infertility (MIM 612997),
and mutations of the dynein genes that encode proteins
of the axonemal dynein cluster (DNAH1 [MIM 603332],
DNAH5 [MIM 603335], DNAH11 [MIM 603339]) and are
associated with asthenozoospermia.8 However, the collec-
tive prevalence of these mutations is extremely low.
NR5A1 (MIM 184757), a member of the nuclear receptor
superfamily, is a key transcriptional regulator of genes
involved in the hypothalamic-pituitary-steroidogenic
axis.9,10 NR5A1, also called steroidogenic factor-1, con-
sists of a DNA-binding domain (DBD) including two zinc
fingers, a flexible hinge region, a ligand-binding domain
(LBD), and two activation function domains: AF-1 and
AF-2.11–13 NR5A1 binds DNA as a monomer, and it is ex-
pressed in Sertoli and Leydig cells of the developing testis
and in Sertoli cells of the prepubertal and adult testis, as
well as in multiple cell types in the fetal, postnatal, prepu-
bertal, andmatureovary.14–16 Inmammalian testis determi-
nation and differentiation, NR5A1 is a positive regulator of
SOX9 (Sry-box9) andAnti-Mu¨llerianHormone (AMH).17,18
NR5A1 also modulates the expression of many factors
involved in cholesterol mobilization and steroid hormone
biosynthesis, including HMG-CoA synthase, steroidogenic
acute regulatory protein (StAR), 3b-hydroxysteroid dehy-
drogenase (3bHSD), and several cytochrome P450 steroidlopmental Endocrinology Research Group, Clinical and Molecular Genetics
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hydroxylase (CYP) enzymes.17 Consistent with its key role
in gonadal development, NR5A1 mutations are associated
with a wide spectrum of phenotypes, including 46,XY
partial and complete gonadal dysgenesis with or without
adrenal failure (MIM 612965), penoscrotal hypospadias,
micropenis with anorchidia, and 46,XX primary ovarian
insufficiency (POI [MIM 612964]).17,19
Here, we demonstrate that heterozygous mutations in
NR5A1 are also associatedwith severe spermatogenic failure
in otherwise healthy men. In an analysis of 315 men
seeking infertility treatment because of spermatogenic
failure, we identified heterozygous missense mutations in
seven men, each mutation located in the hinge region
and proximal LBD of the protein. Each of the mutant
proteins fails to transactivate gonadal promoters optimally.
Our data increase the spectrumof phenotypes that are asso-
ciated with mutations in NR5A1.Subjects and Methods
Patient and Control Populations
The studywas approvedby the Institut Pasteur institutional
review board (RBM 2003/8).We obtained written informed
consent from all patients, family members, and control
subjects who participated in the study. A total of 315 men
who had unexplained reduced sperm counts and were
seeking infertility treatment were included in this study.
All men were recruited from one infertility clinic in Paris.
The men were of mixed ancestry, and they are representa-
tive of the local Parisian population. Patient ancestry was
determined by self reporting, based on responses to
a personal questionnaire,which askedquestions pertaining
to the birthplace, languages, and ethnicity of the partici-
pants, their parents, and their grandparents. Infertile men
with known causes of infertility, including chromosome
anomalies, Y chromosome microdeletions, cryptorchi-
dism, hypospadias, occupational hazards, varicocele, and
lifestyle factors, were excluded from this study. Control
samples were obtained from the HGDP-CEPH panel,
comprising 1064 DNA samples from 52 worldwide popula-
tions. Additional control samples consisted of 140 French
men, 89 men of West African origin (kindly provided by
Dr. Anavaj Sakuntabhai of the Institut Pasteur, Paris), and
96 men of North African origin. Although these men are
healthy, their fertility and semen quality is unknown. To
investigate the degree of rare genetic variation in NR5A1,
we sequenced the entire open reading frame of NR5A1 in
DNA from a panel of 370 fertile men (father of at least two
children) and 359 men with normal semen parameters
(European descent n ¼ 331, North African descent
n ¼ 140, West African descent n ¼ 63, Indian descent
n ¼ 156, East Asian descent n ¼ 30, other descent n ¼ 9).Mutational Analysis of NR5A1
The coding exons of NR5A1 (exons 2–7; NM_004959.4)
were amplified from DNA extracted via conventional tech-506 The American Journal of Human Genetics 87, 505–512, Octoberniques from peripheral-blood lymphocytes of each indi-
vidual and sequenced in accordance with protocols
described elsewhere.19Site-Directed Mutagenesis
NR5A1 expression vectors containing the p.Pro131Leu,
p.Arg191Cys, p.Asp238Asn, and p.Gly212Ser variants
were generated by site-directed mutagenesis (QuikChange,
Stratagene) with the use of wild-type (WT) human NR5A1
cDNA in a pCMX expression vector as a template.19 The
entire coding sequence of all mutant plasmids was
confirmed by direct sequencing prior to functional studies.Transient Gene Expression Assays
Transient gene expression assays for the assessment of
NR5A1 function were performed in 96-well plates (TPP)
with the use of either human embryonic kidney (HEK)
293T cells or a mouse embryonic stem cell line (E14),
Fugene 6 transfection reagent (Roche no. 1 814 443), and
a Dual-Luciferase reporter assay system (Promega) with
pRLSV40 Renilla luciferase (Promega) expression as
a marker of transfection efficiency. pCMX_WT or mutant
NR5A1 expression vectors (10 ng/well) were cotransfected
into HEK293T cells with reporters containing NR5A1 (SF1)
responsive minimal promoters (murine Cyp11a1, human
AMH) (10 ng/well).20,21 Cells were lysed 48 hr later, and
luciferase assays were performedwith the use of a FLUOstar
Optima fluorescence microplate reader (BMG Labtech). All
data were standardized for Renilla activity. Results are
shown as the mean 5 SEM of three independent experi-
ments, each performed in triplicate. A previously described
inactivating mutation of NR5A1, p.Gly35Glu, was
included as control in the transactivation studies.21Cellular Localization Studies
WT NR5A1 cDNA was cloned into a pAcGFP-C1 vector
(Clontech) to allow expression of GFP-tagged NR5A1.
NR5A1 mutations were introduced by site-directed muta-
genesis. Plasmids (0.8 mg/well) were transfected into
tsa201 cells with the use of Lipofectamine 2000 (Invitro-
gen), and images were obtained 24 hr later with a Zeiss Ax-
ioskop microscope and camera.In Vitro Protein Expression
An in vitro rabbit reticulocyte-coupled transcription/trans-
lation system (TNT Quick Coupled Transcription/Transla-
tion System, Promega) was used to express proteins from
the vector constructs. The reactions were performed ac-
cording to the manufacturer’s instructions. In brief,
biotin-labeled protein was expressed by incubation of
1 mg of vector DNA with reticulocyte lysate, amino acid
mixture, RNasin, T7 RNA polymerase, and Transcend
Biotin-Lysyl-tRNA (Promega) in a final volume of 25 ml at
30C for 90 min.8, 2010
Table 1. Mutations in NR5A1 Associated with Spermatogenic Failure
Patient
Age at
Investigation
Ethnic
Origin
Karyo-
type NR5A1 Mutation
Sperm
Count
(106/ml)
N: > 20 3
106/ml
FSH
(IU/l) N:
1.0–10.5 IU/l
LH
(IU/l) N:
0.7–8.0 IU/l
Testosterone
(ng/ml) N:
3.0–10 ng/ml
Inhibin B
(pg/ml) N:
80–400 pg/ml
1 42 Congolese 46,XY p.Gly123Ala (c.368G>C)/
p.Pro129Leu (c.386C>T)a
0 72 34.3 0.49 <15
2 37 Congolese 46,XY p.Gly123Ala (c.368G>C)/
p.Pro129Leu (c.386C>T)a
0 NA NA NA NA
3 29 and 31b Tunisian 46,XY p.Gly123Ala (c.368G>C)/
p.Pro129Leu (c.386C>T)a
12 and 6c 5.1 4.3 5 74
4 41 Sri Lankand 46,XY p.Pro131Leu (c.392C>T) 0 NA NA NA NA
5 25 Congolese 46XY p.Arg191Cys (c.571C>T) 0.3 18.8 10.7 5.7 <15
6 37 French-
Vietnamese
46XY p.Gly212Ser (c.634G>A) 0.8 NA NA NA NA
7 41 Egyptian 46,XY p.Asp238Asn (c.712G>A) 0.7 15.1 6 3 31
NA, not available.
a Mutation was previously reported as associated with POI.
b Patient was evaluated over a 2 yr period.
c Semen quality decreased over a 2 yr period. There was also a reduction in sperm motility and viability.
d Mutation also observed in a woman with POI who is of Tamil origin (unpublished data).Sumoylation of Mutated Proteins
In vitro sumoylation assays were carried out by incubating
in vitro translated pCMXSF1 or p.Asp238Asn vectors with
recombinant Aos1/Uba2 (370 nM), Ubc9 (630 nM), and
SUMO (7 mM) in 30 mM Tris, 5 mM ATP, 10 mM MgCl2,
pH 7.5, at 33C as previously described.22Table 2. Frequency of NR5A1 Mutations and Associated
Phenotypes
Phenotype
No. of
Individuals
No. of Individuals
with Mutation
in NR5A1
Azoospermia
or cryptozoospermia
103 4 (3.9%)
Severe oligozoospermia
or OATs < 1 3 106/ml
46 2 (4.3%)
Moderate oligozoospermia
or OATs 1–10 3 106/ml
50 1 (2%)
Mild oligozoospermia
or OATs 10–20 3 106/ml
116 0
Fertilea 370 0
Normospermica 359 0
a The entire open reading frame of NR5A1 was sequenced in each individual.Results
NR5A1 Mutations Were Identified in Infertile Men
In a screen of 315 men with unexplained spermatogenic
failure who sought infertility treatment, we found seven
heterozygous mutations in NR5A1 by direct sequencing
(Table 1). The seven men carrying NR5A1 mutations did
not report any other members of the family with pheno-
types known to be associated with NR5A1 mutations,
such as POI or 46,XY disorder of sex development (DSD),
and there was no evidence of undervirilization, nor were
there signs of adrenal insufficiency. No other family
members were available for genetic analysis, so it is
unknown whether the mutations are de novo. However,
three men of African origin carried a double NR5A1 muta-
tion (p.Gly123Ala/p.Pro129Leu; NP_004950) that we have
previously reported as being associated with POI in a girl of
African origin, suggesting that this is probably a founder
mutation.19 One man, who carried the p.Gly123Ala/
p.Pro129Leu double mutation, had a progressive loss of
germ cell quantity and quality over a 2 yr period (Table
1). With one exception, NR5A1mutations were associated
with severe spermatogenic failure (Table 2). We did not
observe mutations in men with mild oligozoospermia.
These mutations were not observed in over 2100 control
samples (4200 alleles), and no rare allelic variants wereThe Americfound after analysis of the entire coding region of NR5A1
in 370 fertile (father of at least two children) or 359 normo-
spermic men (Table 2). This indicates that these mutations
are pathogenic. All mutations fall within the evolution-
arily conserved hinge region (amino acids 95–225), or
the proximal portion of the LBD of NR5A1 (Figure 1).
NR5A1 Mutations Are Associated with Altered
Hormonal Profile and Gonad Histology
Hormonal data were available for four of the men carrying
NR5A1mutations (Table 1). Testosterone levels were at the
lower limit of the normal range in subject 7 and below the
normal range in subject 1. Serum levels of inhibin B,
a marker of spermatogenesis and a predictor of the pres-
ence of testicular sperm in men with nonobstructivean Journal of Human Genetics 87, 505–512, October 8, 2010 507
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Figure 1. Distribution of NR5A1 Mutations Associated with Spermatogenic Failure in Relation to the Protein
The functional domains of the NR5A1 protein are shown. The DNA-binding domain containing two zinc-finger motifs is indicated. The
FtzF1 box stabilizes protein binding to DNA. The hinge region is important for stabilizing the ligand-binding domain and interacts with
other proteins that control NR5A1 transcriptional activity. The AF2 domain recruits cofactors necessary for NR5A1 transactivating
activity. The position of the amino acid change and its evolutionary conservation are shown for each of the mutations identified.azoospermia, were low in all four men. Serum follicle-stim-
ulating hormone (FSH) and luteinizing hormone (LH)
levels were elevated above the normal values in cases 5
and 1, whereas case 7 had elevated serum FSH and
LH levels within the normal range. Gonadal histology
was available for case 1, who carries the p.Gly123Ala/
p.Pro129Leu double mutation (Figure 2). This showed
a hypoplastic testis with few germ cells and areas of marked
fibrosis and hyalinization.
NR5A1 Mutations Do Not Affect Nuclear Localization
but Alter the Transactivation Ability of the Protein
To assess the impact of the NR5A1 mutations on nuclear
localization, we generated WT and mutant GFP-NR5A1508 The American Journal of Human Genetics 87, 505–512, Octoberconstructs by cloning WT NR5A1 cDNA in frame into
a pAcGFP-C1 vector to produce a fusion protein of
NR5A1 with a monomeric green fluorescent protein
(GFP) tag at its amino-terminal end. Mutant pAcGFP-C1-
NR5A1 vectors were generated by site-directed mutagen-
esis, with the WTconstruct used as a template. The cellular
localization of both WT and mutant GFP-NR5A1 fusion
proteins (green), generated and expressed in tsa201 cells
with the use of the pAcGFP-C1 vector, showed strong
nuclear localization with relative nucleolar exclusion and
very occasional nuclear subfoci (Figure 3).
To assess the functional properties of NR5A1, we per-
formed site-directed mutagenesis by using WT human
NR5A1 cDNA in a pCMX expression vector as a template.Figure 2. Gonadal Histology of Subject 1
Photomicrographs demonstrating abnor-
mal testicular histology showing areas of
interstitial fibrosis (A–D) and hyaliniza-
tion (C), with scattered residual abnormal
seminiferous tubules containing occa-
sional germ cells but no normal spermato-
genesis. Within the fibrous areas, residual
tubular structures are present (D). No
normal testicular tissue is present. (ST,
seminiferous tubules; *, interstitial fibrosis;
HT, hyalinised tubule; RT, residual tubular
structures).
8, 2010
Figure 3. Cellular Localization of NR5A1 Mutants
Cellular localization of GFP-SF1 fusion proteins (green), generated
and expressed in tsa201 cells with the use of a pAcGFP-C1 vector.
WT NR5A1 shows strong nuclear localization, with relative nucle-
olar exclusion and very occasional nuclear subfoci. An expression
and localization pattern similar to that of the WT was seen for all
the other mutant proteins.
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Figure 4. Assays of NR5A1 Transcriptional Activity
The transcriptional activity of WT NR5A1 and variants associated
with male infertility was studied with the use of Cyp11a1 (A) and
AMH (B) promoters in HEK293T cells. A previously described inac-
tivatingmutation ofNR5A1, p.Gly35Glu,was included as a control
in the transactivation studies. Results are expressed as a percentage
ofWTNR5A1 activity, which is considered to be 100%. Data repre-
sent the mean of three independent experiments, each performed
in triplicate. The T bars represent the SEM.We have previously demonstrated that the NR5A1
p.Pro129Leu variant lacks transcriptional activity, and
this mutant protein is associated with 46,XX POI.19 The
other mutant proteins had altered biological activity in
cotransfection luciferase assays driven by NR5A1-depen-
dent gonadal promoters. A quantitative reduction in the
transactivation of both the Cyp11a1 (encoding P450scc)
promoter and the AMH (encoding anti-Mu¨llerian
hormone) promoter was observed in transactivation assays
of the mutations p.Pro131Leu, p.Arg191Cys, p.Gly212Ser,
and p.Asp238Asn (NP_004950) using HEK293T cells
(Figures 4A and 4B). Similar results were obtained in tran-
sient gene expression assays using murine E14 embryonic
stem cells (data available on request). These in vitro func-
tional assays demonstrated that each mutation may lead
to a functional disturbance of the NR5A1 protein and
may affect the regulation of its downstream target genes
during gonadal development and function.The AmericNR5A1 Mutation p.Asp238Asn Does Not Affect
Sumoylation of NR5A1
The NR5A1 p.Asp238Asn mutation was analyzed for its
ability to undergo sumoylation because it lies immediately
carboxy terminal to a putative SUMO-binding motif.
No difference was observed between the efficiency of
pCMX-SF1 and pCMX-Asp238Asn for undergoing
in vitro sumoylation (data available upon request).Discussion
In this study, we provide evidence thatmutations inNR5A1
(encoding steroidogenic factor 1) are associated with unex-
plained severe spermatogenetic failure in otherwisehealthy
men. This considerably broadens the range of phenotypes
associated with mutations in NR5A1, which to date have
been reported only in association with more severe forms
of gonadal dysgenesis or with significant genital anomaliesan Journal of Human Genetics 87, 505–512, October 8, 2010 509
such as penoscrotal hypospadias, anorchia, or unde-
scended testes.17 These data therefore support the hypoth-
esis of Skakkebaek and coworkers that a subset of men with
spermatogenic failurehave amild formof testicular dysgen-
esis syndrome.1,23 Although male factor infertility is the
primary presenting feature leading to medical evaluation
in these cases, our data show that this subset of men with
severe azoospermia may also be at risk of endocrine
dysfunction and failing testosterone with increasing age.
It is well established that approximately 12%–15% of men
with idiopathic spermatogenic failure have reduced serum
testosterone levels and elevated LH levels as compared to
the normal range.24 It has beenproposed that someof these
men may have mild forms of testicular dysgenesis.24 Our
data suggest that those individuals with NR5A1mutations
may represent part of this group.
The mutations in NR5A1 reported here were all missense
mutations in the hinge region or proximal ligand-binding
domain of the protein. We found the p.Gly123Ala/
p.Pro129Leu double mutation in three individuals of
Central or North African ancestry, and we have described
this change previously in aWest African girl with POI, sug-
gesting that this mutation may be present at low levels in
the general population.19 The transmission of the muta-
tion may be explained by a progressive loss of gonadal
function over time, so that fecundity is achieved in early
adulthood before the development of spermatogenic
failure. In this study, two men who carried this mutation
presented with azoospermia at 37 and 42 yrs of age. Indi-
vidual 3, who also carried this mutation, showed a progres-
sive decline in both sperm quantity and quality over a 2 yr
period, from 29 yrs to 31 yrs of age. This may represent
a progressive aging phenomenon or may possibly repre-
sent different expression of the phenotype as a result of
other genetic or environmental modifiers. The absence of
this allelic variant in the control population suggests that
this is not a frequent genetic alteration. Furthermore, the
absence of any changes in NR5A1 after direct sequencing
of more than 600 fertile or normospermic men suggests
that rare allelic variants in this gene are not common,
other than the well-described p.Gly146Ala polymorphism
(rs1110061).
A number of molecular mechanisms may explain the
spermatogenic failure associated with NR5A1 mutations.
In theNr5a1 Leydig cell-specific knockout, mice had hypo-
plastic testes in which the lumens of the seminiferous
tubules failed to open and spermatogonia never developed
into mature sperm.25 These mice also showed reduced
expression of two key genes in testosterone biosynthesis,
Cyp11a and StAR.25 In a study of azoospermic patients,
expression levels of NR5A1 in gonadal tissue correlated
positively with serum testosterone concentrations, sug-
gesting a direct connection between these two factors.26
Alternatively, impairment of reproductive function could
result, in part at least, from anomalies of the anterior pitu-
itary. Mice that lack Nr5a1 specifically in their pituitary
have reduced levels of LH and FSH.27 These mice show510 The American Journal of Human Genetics 87, 505–512, Octobermarked hypogonadism with a reduction in testis volume,
a decreased number of Leydig cells, and an absence of
mature spermatids, resulting in infertility.27 However, our
data show normal or elevated serum FSH and LH levels
together with a normal or low testosterone level in men
carrying an NR5A1 mutation that suggests a predominant
testicular phenomenon.
We show that the NR5A1 mutants associated with male
infertility show impaired activation of two of the NR5A1
target genes, AMH and Cyp11a1. Several molecular mecha-
nisms could explain the germ cell loss associated with
these mutations. The mutations fall within the hinge
region (amino acids 95–225) and proximal portion of the
LBD, and a number of physical interactions and functional
activities have been mapped to this portion of the
protein.12 Phosphorylation of Ser 203 in the hinge region
enhances the interaction of GRIP1 and SMRTwith the AF1
and AF2 regions of NR5A1, whereas sumoylation of lysines
within the hinge region increases interactions with DEAD
box proteins and results in transcriptional repression.28,29
NR5A1 stimulation of CYP17A1 expression is augmented
by a direct physical interaction with the protein translin.30
This interaction is mediated through amino acids 170–225
of the hinge region of NR5A1.30 Modulation of NR5A1
transcriptional activation via the hinge region has also
been described for the coactivator SRC-1, which potenti-
ates the activity of SF-1 by utilizing the highly-conserved
AF-2 hexamer at the C terminus of the protein and a prox-
imal interaction domain at residues 226–230.16 Finally,
in vitro studies have suggested that NR5A1 receptor phos-
phorylation may be modulated by the herbicide atrazine,
leading to disruption of NR5A1-related gene networks
and potential alterations in endocrine development and
function.31 The clustering of the mutations in a specific
region of the molecule could suggest a common mecha-
nism leading to germ cell loss, or even altered sensitivity
to environmental disruptors, but additional studies of
larger cohorts of infertile men are required to see whether
such a genotype-phenotype correlation is robust.
We conclude that approximately 4% of men with other-
wise unexplained severe spermatogenic failure carry muta-
tions in NR5A1. The data also suggest that some forms of
male infertility may be an indicator of mild testicular
dysgenesis, underlining a need for careful clinical investi-
gation of men presenting with infertility and incongruous
testosterone and gonadotropin levels.Acknowledgments
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